Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is poised for significant revenue growth, with projections indicating a substantial sales acceleration in 2026, where Obe-cel and other therapies could drive revenue estimates to $167 million, reflecting a 220% year-over-year increase. The company's guidance for Aucatzyl revenues suggests a robust 60-80% increase in 2026, bolstered by the expansion of its network to over 80 locations. Additionally, the rising adoption rates of CAR-T therapies in the UK, coupled with favorable reimbursement changes for bispecifics, underpin the positive outlook for Autolus Therapeutics's financial performance.

Bears say

Autolus Therapeutics PLC has experienced a significant decline in its stock price, dropping approximately 48% since July 2025, primarily due to stagnant revenue growth in its lead product, Aucatzyl, which is constrained by manufacturing capacity issues following a change in Medicare guidelines. The company's financial outlook is further complicated by the necessity for an estimated $1 billion in additional capital through 2038, alongside concerns about its cash runway extending only until 2027. Additionally, risks related to the efficacy and safety of its clinical programs, regulatory decisions, and competitive pressures could impact the company’s ability to meet its strategic goals and financial projections.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.